Conclusion: These results demonstrate the feasibility to generate primary allogeneic T-cell responses against MCL-APC, and may provide new immunotherapeutic tools to further exploit the GvL effect following allogeneic SCT in patients with MCL.
Although in general MCL is initially responsive to conventional chemotherapy or to high-dose chemoradiotherapy followed by autologous stem cell transplantation (SCT), persistent remissions are usually not achieved reflected in the absence of a plateau phase in the survival curves 3, 4 . The addition of rituximab to autologous SCT as an in vivo purging agent or as maintenance therapy appears promising, but has not yet definitively shown to result in a survival benefit [5] [6] [7] .
Allogeneic SCT is currently being explored as a treatment modality in patients with advanced or relapsed chemosensitive MCL. Complete sustained remissions have been observed after allogeneic SCT illustrating susceptibility of MCL cells to a graft-versus-lymphoma (GvL) effect 5, 8 . High treatment related mortality (TRM) has hampered large scale application of allogeneic SCT in this extensively pretreated older patient population. Allogeneic SCT following reduced-intensity conditioning (RIC) has been shown to be feasible and resulted in a lower TRM, allowing the application of non-selected donor lymphocyte infusion (DLI) [9] [10] [11] [12] . However, acute and chronic graft-versus-host disease (GvHD) caused by alloreactive T cells present in the graft and/ or in the DLI and persistence or recurrence of MCL after allogeneic SCT has limited favourable long-term outcomes 13 . Therefore, both the specificity of the immune reactivity in the context of allogeneic SCT, as well as the magnitude of the immune response specific for MCL cells have to be improved. The use of T-cell depleted grafts avoiding the risk of GvHD, followed by in vitro selected alloreactive T cells with specificity for the MCL cells or for hematopoiesis-restricted minor histocompatibility antigens (mHag) could be an attractive approach, and may induce complete remissions with only minor graft-versus-host disease (GvHD) 14 .
Malignant B cells inefficiently induce allogeneic T-cell responses despite their strong expression of
HLA class I and class II due to inadequate expression of costimulatory and adhesion molecules [15] [16] [17] .
However, both normal and malignant B cells highly express CD40 molecules. Ligation of these receptors induces expression of the costimulatory molecules CD80 and CD86, adhesion molecules such as CD54 and CD58, and upregulates cytokine production [16] [17] [18] [19] [20] [21] . Stimulation of normal B cells can also be initiated by activating toll-like receptor (TLR) 9. TLR 9, expressed on normal and various neoplastic B cells [22] [23] [24] [25] , detects CpG motifs within bacterial DNA and induces upregulation of costimulatory molecules on these cells. Synthetic CpG oligodeoxynucleotide (ODN) 2006 mimic microbial DNA and has the ability to activate normal and malignant B cells 26 . Transformation of B cell malignancies, including B-cell chronic lymphocytic leukemia, follicular lymphoma and hairy cell leukemia, into antigen-presenting cells (APC) has been studied previously 15, 17, 20, 21, [27] [28] [29] , but the modification of MCL cells into APC and the generation of MCL-reactive T-cell responses have not been reported.
In this study, we hypothesized that by transforming MCL cells into professional APC and using these MCL-APC to stimulate HLA-matched donor T cells, the generation of MCL-reactive cytotoxic T lymphocytes (CTL) lines will be possible. We first examined the stimulatory capacity of cytokines, including the proinflammatory cytokines TNF-and interferon-, the B-cell activating cytokine interleukin (IL)-4 30 , and the MCL-stimulating cytokine IL-10 31 and the additional triggering of the TLR9
by the synthetic agonist CpG ODN 2006, or triggering CD40 with CD40 ligand transfected fibroblasts (tCD40L) to upregulate costimulatory molecules on MCL cells, and to induce the production of IL-12 by these cells. Using CD40-activated MCL cells as stimulator cells, we could demonstrate that MCLreactive mHag-specific CTL lines and clones from HLA class I-matched donors could be generated.
These anti-MCL T-cell responses may be used to treat patients, suffering from relapse of MCL after allogeneic SCT.
Material and methods

Cell samples
After informed consent peripheral blood samples were obtained from 6 patients with MCL in the leukemic phase. The diagnosis of MCL was confirmed by detection of cyclin D 1 overexpression using cytohistochemical staining and verification of the t(11;14) translocation by karyotype or interphase fluorescence in situ hybridization (FISH) 32 . The patient characteristics are shown in table 1. Mononuclear cells (MNC) were isolated from peripheral blood samples by Ficoll density separation, and cryopreserved. The percentage of CD5+/CD19+ MCL cells in the MNC fraction was always higher than 90% . HLA-A, -B, and -C typing of patients was performed by standard serology methods, and HLA-DR and -DQ typing was done by DNA analysis using sequence specific primers. To induce T-cell responses, MNC from a fully HLA class I-matched URD and an HLA-A-and HLA-B-matched unrelated donor (URD) were tested against MCL 3 and MCL 4, respectively (table 2) . Immunophenotyping and cytokine analysis clones were harvested, and tested for specific cytolytic activity against the primary MCL cells, CD40 activated MCL cells, and PHA blasts from patient and donor. As read-out system for T-cell-mediated cytotoxicity, our recently developed carboxyfluorescein diacetate succinimidyl ester (CFSE)-based cytotoxicity assay was used 35 .
CFSE-based cytotoxicity assay
The CFSE-based cytotoxicity assay facilitates the quantitative analysis of susceptibility to T-cell- 
Statistical analysis
Statistical significance of differences was determined by the paired two-tailed Student' s t-test or by the Wilcoxon test using the absolute values.
Results
Expression and upregulation of adhesion and costimulatory molecules on MCL cells.
To determine cell surface expression of the adhesion molecules CD54 and CD58, and the costimulatory molecules CD40, CD80, CD86 and CD83, immunophenotyping of freshly isolated MCL cells from 6 patients was performed. lines generated against MCL-APC was measured using the CFSE-based cytotoxicity assay 35 (see Material and methods) with CFSE-labeled primary MCL cells, MCL-APC cells, and PHA blasts from the patients and donors as target cells. As illustrated in figure 4 , the CD8 + CTL lines derived from the donors effectively killed the primary MCL cells, the MCL-APC, the PHA blasts from the patient, and not the PHA blasts from the donor in a 12 hours CFSE cytotoxicity assay. indicating that the immunogenic antigen is not MCL-or B-cell-specific, but most likely mHag-specific.
As we previously illustrated for patients with acute leukemia's 14, 39, 40 , repeated stimulation of donor T cells with leukemic cells results in the generation of T-cell responses against mHag with relative specificity for the malignant cells. Therefore, although other patient-derived APC may be capable of eliciting mHag specific T-cell responses, MCL-derived APC likely will skew the immune response toward recognition of MCL-specific antigens or mHags highly expressed on the MCL cells thus leading to a more specific and efficient T-cell response.
In summary, our study shows that T cell anergy to primary MCL cells can be reversed by transforming MCL cells into professional malignant APCs using CD40 ligation and provides the first evidence that using these MCL-APCs as stimulators MCL-reactive mHag-specific CD8 + CTL lines and clones can be readily generated from MNC of HLA class I-matched donors. Two recent reports demonstrated the feasibility of RIC allogeneic SCT as salvage therapy in patients with advanced MCL 41, 42 . After allogeneic SCT sensible RT-PCR techniques for minimal residual disease and donor chimerism analysis enable to predict disease recurrence. The administration of DLI can lead to long-term remissions, but effectiveness may be limited due to low immunogenicity of MCL cells and the development of acute or chronic GvHD, caused by non-selected donor T cells. In this setting the application of mHag-specific CTLs, which preferently kill MCL cells and not non-hematopoietic targets
